… To overcome this predicament, the signaling of receptor … not show the benefit in
gemcitabine-refractory metastatic PDAC … , cixutumumab to Erlotinib and G did not improve PFS or …

… in phase II/III trials, except erlotinib, an epidermal growth factor … , or metastatic pancreatic
cancer 569 Erlotinib+gemcitabine; … untreated metastatic pancreatic cancer 116 Cixutumumab+…

… architecture of metastatic pancreatic cancer beyond the BRCA … one to show an improved
OS with the erlotinib/gemcitabine … and the monoclonal antibody cixutumumab did not improve …

… receptors or insulin-like growth factor receptor (… gemcitabine and MK-0646 combination
but no difference in PFS, and there was no benefit in dual receptor blockade by adding erlotinib. …

… in pancreatic cancer, such as dysregulation in the KRAS and TGFβ signaling pathways, have
… approved for patients with metastatic PDAC having failed gemcitabine therapy. Onivyde …

… phase I study of the IGF-1R antibody cixutumumab plus the mTOR inhibitor temsirolimus in
patients with metastatic prostate cancer, reported grade 1 or 2 … dasatinib plus gemcitabine …

… cixutumumab, another IGF1R monoclonal antibody antagonist, with erlotinib and GEM failed
to show a … Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib …

… for which an anti-programmed death receptor 1 (PD-1) antibody … of these growth factors
include insulin-like growth factors, … erlotinib, cixutumumab, and gemcitabine versus gemcitabine …

… domain of the type I insulin-like growth factor receptor (IGF-IR), … On the other hand,
cixutumumab (IMC-A12), a fully human … erlotinib and gemcitabine in a phase 1b/2 study in …

… of the insulin-like growth factor 1 receptor (IGF-1R) signaling … AKT and ERK1/2, proliferation,
migration and metastasis. An … combination with gemcitabine in pancreatic cancer has shown …